grant
Aldosterone and the menopausal transition's increase in blood pressure and cardiovascular risk
Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 20 May 2024Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY2025ACE InhibitorsALDOSActive Follow-upAffectAldosteroneAldosterone ReceptorAldosterone SynthaseAngiotensin I-Converting Enzyme InhibitorsAngiotensin ReceptorAngiotensin-Converting Enzyme AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin-Forming EnzymeAngiotensinogenAngiotensinogenaseAnti-Hypertensive AgentsAnti-Hypertensive DrugsAnti-HypertensivesApoplexyBP homeostasisBP regulationBiometricsBiometryBiostatisticsBlood PlasmaBlood PressureBlood SerumBrain Vascular AccidentCYP11B2 geneCardiacCardiac infarctionCardiovascularCardiovascular Body SystemCardiovascular DiseasesCardiovascular Organ SystemCardiovascular systemCause of DeathCerebral StrokeCerebrovascular ApoplexyCerebrovascular StrokeCessation of lifeChronic Kidney FailureChronic Renal DiseaseChronic Renal FailureCytochrome P450, Subfamily XIB, Polypeptide 2DataDeathDevelopmentDiabetic Kidney DiseaseDiabetic NephropathyDrugsEndocrine Gland SecretionEndocrine systemEndocrine/Metabolic Organ SystemEpidemiologic ResearchEpidemiologic StudiesEpidemiologic analysisEpidemiological StudiesEpidemiologyEpidemiology ResearchEstrogen declineEstrogensEventFailureFemaleGlomerular Filtration RateGoalsHealthHeart VascularHormonal SystemHormonesHypertensinogenHypertensionHypotensive AgentHypotensive DrugsIndividualKidneyKidney Urinary SystemKininase II AntagonistsKininase II InhibitorsLifeLinkLogistic RegressionsLongitudinal StudiesMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasurementMeasuresMedicationMenopauseMensesMenstruationMetabolic/Endocrine Body SystemMidlife womenMineralocorticoid ReceptorModelingMyocardial InfarctMyocardial InfarctionOutcomePatientsPerimenopausalPerimenopausePharmaceutical PreparationsPlasmaPlasma SerumPopulationPost-MenopausePost-menopausal PeriodPostmenopausal PeriodPostmenopausePrevalenceProangiotensinProbabilistic ModelsProbability ModelsProductionReninRenin-Angiotensin-Aldosterone SystemRenin-SubstrateResistant HypertensionReticuloendothelial System, Serum, PlasmaRiskRoleSamplingSerumStatistical ModelsSteroid 11/18-Beta-HydroxylaseSteroid 18-OxidaseStrokeSystemTestingTherapeutic EstrogenTherapeutic HormoneTimeUnited StatesVascular Hypertensive DiseaseVascular Hypertensive DisorderVisitWomanWomen's mortalityWomen's studyactive followupafter menopauseantagonismantagonistanti-hypertensionblood pressure elevationblood pressure homeostasisblood pressure regulationbrain attackcardiac infarctcardiovascular disease riskcardiovascular disordercardiovascular disorder riskcardiovascular healthcardiovascular riskcardiovascular risk factorcerebral vascular accidentcerebrovascular accidentchronic kidney diseasecirculatory systemcoronary attackcoronary infarctcoronary infarctiondeath among femalesdeath among womendeath in femalesdeath in womendeath rate among womendeath rate in womendecline in estrogendecrease estrogendecrease in estrogendevelopmentaldrug/agentelevated blood pressureendocrine gland/systemepidemiologicepidemiologic evaluationepidemiologic investigationepidemiologicalepidemiology studyexperiencefemale at midlifefemale deathfemale mortalityfemale studyfollow upfollow-upfollowed upfollowing menopausefollowupheart attackheart infarctheart infarctionhigh blood pressurehyperpiesiahyperpiesishypertension treatmenthypertensive diseasehypertensive disorderimprovedincrease in blood pressureincreased blood pressureinhibitorinsightlong-term studylongitudinal outcome studiesmalemenmenopause transitionmenstrual periodmid-life femalemiddle-aged femalemiddle-aged womenmonthly periodmonthly periodsmortalitymortality among femalesmortality among womenmortality in femalesmortality in womenneglectnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyolder womenoptimal therapiesoptimal treatmentspast menopauseperi-menopausalperi-menopausepost-menopausalpostmenopausalpostmenopausal statuspreventpreventingreduced estrogenregulate BPregulate blood pressurerenalrevascularizationsocial rolestatistical linear mixed modelsstatistical linear modelsstrokedstrokesstudy among femalesstudy among womenstudy in femalesstudy in womenstudy on femalesstudy on womenstudy within womentransition to menopausetransitional menopausewomen at midlifewomen in midlifewomen's deathwomen's death rate♀♂
Description preview
There is more female hypertension-related mortality than male. Although women’s blood pressure is lower than
men’s in younger life, after menopause the reverse is true. A decrease in estrogen plays a role in women’s
midlife increase in blood pressure. However, factors that modify the extent of this increase in individuals are
not known.
The…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click